This year's biggest oncology conference delivered some surprisesand gave investors plenty to look forward to in the months ahead. Loxo Oncology Inc. (NASDAQ: LOXO), and TG Therapeutics (NASDAQ: TGTX)are already having a great year that could get a lot better, while recently beaten down Nektar Therapeutics (NASDAQ: NKTR)will get a chance to redeem itself.
3 Cancer Stocks That Could Soar in the Second Half of 2018
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться